Reduced incidence of end stage renal disease among the elderly in Denmark: An observational study

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Heaf, James G ^a   Wehberg, Sonja ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

ACE inhibition; Antihypertensive therapy; Epidemiology; ESRD; Hypertension; Uremia progression

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DENMARK; FEMALE; HUMAN; INCIDENCE; KIDNEY FAILURE; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DENMARK; FEMALE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PRESCRIPTIONS; RISK FACTORS; TREATMENT OUTCOME; UREMIA;

EID: 84866843551     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-131     Document Type: Article

References (24)

1. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. N Engl J Med 1994 330 877 884 10.1056/NEJM199403313301301 8114857 (Pubitemid 24094966)
2. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Lancet 2005 365 939 946 10.1016/S0140-6736(05)71082-5 15766995 (Pubitemid 41071427)
3. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. JAMA 2002 288 2421 2431 10.1001/jama.288.19.2421 12435255 (Pubitemid 35340538)
4. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Kamper AL, Strandgaard S, Leyssac PP, Am J Hypertens 1992 5 423 430 1637513
5. Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria. Kamper AL, Strandgaard S, Leyssac PP, Nephrol Dial Transplant 1995 10 1182 1188 7478121
6. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, N Engl J Med 2001 345 870 878 10.1056/NEJMoa011489 11565519
7. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Brenner BM, Cooper ME, De ZD, Keane WF, Mitch WE, Parving HH, et al. N Engl J Med 2001 345 861 869 10.1056/NEJMoa011161 11565518
8. Efficacy and safety of benazepril for advanced chronic renal insufficiency. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. N Engl J Med 2006 354 131 140 10.1056/NEJMoa053107 16407508 (Pubitemid 43076710)
9. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), Lancet 1997 349 1857 1863 9217756
10. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. N Engl J Med 1996 334 939 945 10.1056/NEJM199604113341502 8596594 (Pubitemid 26114159)
11. Managing kidney disease with blood-pressure control. Wuhl E, Schaefer F, Nat Rev Nephrol 2011 7 434 444 10.1038/nrneph.2011.73 21691318
12. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Sorensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B, Kidney Int 2006 70 187 191 10.1038/sj.ki.5001516 16688116 (Pubitemid 44000137)
13. The dilemma of renal replacement therapy in patients over 80years of age. Dialysis should not be withheld. Schaefer K, Rohrich B, Nephrol Dial Transplant 1999 14 35 36 10463210 (Pubitemid 29041862)
14. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Kramer A, Stel V, Zoccali C, Heaf J, Ansell D, Gronhagen-Riska C, et al. Nephrol Dial Transplant 2009 24 3557 3566 10.1093/ndt/gfp519 19820003
15. U.S. Renal Data System, USRDS 2010 Anual Data Report Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease 2011 2 388
16. Strict blood-pressure control and progression of renal failure in children. Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al. N Engl J Med 2009 361 1639 1650 19846849
17. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ, Am J Kidney Dis 1996 27 489 495 10.1016/S0272-6386(96)90158-4 8678058 (Pubitemid 26106596)
18. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Lancet 1999 354 359 364 10.1016/S0140-6736(98) 10363-X 10437863 (Pubitemid 29355751)
19. Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 1996 7 2616 2626 8989740
20. Smoking is associated with progression of diabetic nephropathy. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M, Diabetes Care 1994 17 126 131 10.2337/diacare.17.2.126 8137682 (Pubitemid 24035307)
21. Danmarks Statistik 2011 www.statistikbanken.dk/statbank5a/
22. The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration. Hommel K, Rasmussen S, Madsen M, Kamper AL, Nephrol Dial Transplant 2010 25 947 951 10.1093/ndt/gfp571 19861312
23. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Charlson ME, Pompei P, Ales KL, MacKenzie CR, J Chronic Dis 1987 40 373 383 10.1016/0021-9681(87)90171-8 3558716 (Pubitemid 17055592)
24. RiskDiff: a web tool for the analysis of the difference due to risk and demographic factors for incidence or mortality data. Valls J, Cleries R, Galvez J, Moreno V, Gispert R, Borras JM, et al. BMC Public Health 2009 9 473 10.1186/1471-2458-9-473 20021655